← Back
product
Epanova
Last discussed Sep 14, 2026
A prescription omega-3 fatty acid drug containing a combination of EPA and DHA (primarily EPA) developed for cardiovascular outcomes, tested in the STRENGTH trial.
Recently discussed in
407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more
Michael Davidson · Sep 14, 2026
What creators say
MD
Michael Davidson
mentioned
Used for: Cardiovascular outcomes via triglyceride lowering; tested in the STRENGTH trial at 4 grams
vs: Compared to icosapent ethyl (EPA-only, REDUCE-IT trial) which showed benefit;...
"I was involved in developing an omega-3 for heart disease called Epanova. We went to an outcome study and it didn't work, but it was DHA and EPA but mostly EPA had some DHA."
More from Michael Davidson →Keep exploring
Topics
About this data
- ✓48,000+ mentions extracted from real podcast transcripts
- ✓Every quote links to the source episode
- ✓Sponsored mentions are always labeled
- ✓Critical takes are shown, never filtered out
Get an email when a new creator recommends it